tiprankstipranks
Trending News
More News >
MDxHealth (MDXH)
NASDAQ:MDXH
US Market
Advertisement

MDxHealth (MDXH) Earnings Dates, Call Summary & Reports

Compare
188 Followers

Earnings Data

Report Date
Mar 04, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.13
Last Year’s EPS
-0.14
Same Quarter Last Year
Based on 3 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call highlighted robust revenue and volume growth, improved gross margins, and a successful acquisition of ExoDx. However, these positives were tempered by the discontinuation of the germline offering and ongoing net and operating losses. Overall, the sentiment reflects a company making strategic adjustments for future growth while managing current financial challenges.
Company Guidance
During the third quarter of 2025, MDxHealth reported significant progress in several key areas, demonstrating strong operational performance and strategic growth. The company achieved an 18% increase in revenue, reaching $27.4 million compared to the prior year's $23.3 million, driven in part by a 37% increase in total billable volume, with tissue-based tests growing by 18% and liquid-based tests by 65%. The gross profit improved by 25% to $17.9 million, resulting in a gross margin of 65.2%, up from 61.2% the previous year. The company's operating loss reduced by 57% to $2.6 million, and the net loss decreased by 28% to $8 million. Notably, adjusted EBITDA turned positive at $1 million, compared to a negative $3.8 million in 2024. Cash and cash equivalents stood at $32 million by the end of the quarter. The integration of the Exosome Diagnostics (ExoDx) acquisition is a priority, with a strategic sales force expansion from 50 to 60 reps across eight regions to optimize cross-selling opportunities. The company also decided to set aside its germline offering, originally anticipated to contribute significantly to the 2025 revenue guidance of $108-$110 million, to focus on integrating and leveraging the ExoDx acquisition.
Strong Revenue Growth
Q3 revenue reached $27.4 million, representing an 18% increase over the previous year, despite the strategic decision to forego the germline offering.
Positive Adjusted EBITDA
Q3 marked the second consecutive quarter of positive adjusted EBITDA at $1 million, following the first profitable quarter in Q2.
Significant Volume Growth
Total billable volume grew by 37% compared to the prior year, with liquid-based tests increasing by 65% and tissue-based tests by 18%.
Gross Margin Improvement
Gross margins improved to 65.2% from 61.2% in Q3 2024, driven by test mix and operational efficiencies.
Successful ExoDx Acquisition
The company successfully closed the ExoDx acquisition, expanding the sales organization and enhancing cross-selling opportunities.

MDxHealth (MDXH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

MDXH Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 04, 2026
2025 (Q4)
-0.13 / -
-0.14
Nov 12, 2025
2025 (Q3)
-0.11 / -0.16
-0.460.00% (+0.24)
Aug 05, 2025
2025 (Q2)
-0.12 / -0.15
-0.4264.29% (+0.27)
May 14, 2025
2025 (Q1)
-0.13 / -0.19
-0.3138.71% (+0.12)
Feb 26, 2025
2024 (Q4)
-0.19 / -0.14
-0.3964.10% (+0.25)
Nov 06, 2024
2024 (Q3)
-0.27 / -0.40
-0.40.00% (0.00)
Aug 21, 2024
2024 (Q2)
-0.28 / -0.42
-0.4-5.00% (-0.02)
May 01, 2024
2024 (Q1)
-0.30 / -0.31
-0.538.00% (+0.19)
Mar 06, 2024
2023 (Q4)
-0.21 / -0.39
-1.0663.21% (+0.67)
Nov 08, 2023
2023 (Q3)
-0.30 / -0.40
-0.520.00% (+0.10)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

MDXH Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2025
$4.12$3.97-3.64%
Aug 05, 2025
$2.49$2.75+10.44%
May 14, 2025
$1.78$1.90+6.74%
Feb 26, 2025
$1.83$1.86+1.64%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does MDxHealth (MDXH) report earnings?
MDxHealth (MDXH) is schdueled to report earning on Mar 04, 2026, Before Open (Confirmed).
    What is MDxHealth (MDXH) earnings time?
    MDxHealth (MDXH) earnings time is at Mar 04, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is MDXH EPS forecast?
          MDXH EPS forecast for the fiscal quarter 2025 (Q4) is -0.13.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis